Results 11 to 20 of about 77,746 (246)

Effects of Systemic and Local Interferon Beta-1a on Epidural Fibrosis [PDF]

Asian Spine Journal, 2016
Study DesignLevel 1 randomized controlled study.PurposeTo investigate the effects of systemic and local interferon-beta-1a (IFN-β-1a) on prevention of epidural fibrosis using histopathological parameters.Overview of LiteratureEpidural fibrosis involves ...
Mevlüt Özgür Taşkapılıoğlu, Semra Işık, Şeref Doğan, Gonca Özgün, Gökhan Ocakoğlu, Nesrin Uğraş   +5 more
doaj   +1 more source

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study

Advances in Human Biology, 2023
Introduction: Although a long time past since COVID-19 was broken out, it is hard to determine which pharmacological combination regimen is more efficacious. The present study aimed to evaluate the efficacy of lopinavir/ritonavir (LPV/r) plus interferon (
Motahareh Amirizadeh, Fatemeh Shafie Sarvestani, Farid Khorrami, Omid Safa, Parivash Davoodian, Mehdi Hassaniazad, Boshra Akhlaghi, Mohammad Fathalipour   +7 more
doaj   +1 more source

The Therapeutic Effect of Avonex, Rebif and Betaferon on EDSS and Relapse in Multiple Sclerosis: A Comparative Study [PDF]

Acta Medica Iranica, 2010
We aimed to compare the therapeutic effect of Avonex (Av), Betaferon (Be) & Rebif (Re) on the Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS). Ninety patients referring to Farshchian Hospital were entered in this study.
Mehrdokht Mazdeh, Saeed Afzali, Mahmood Reza Jaafari   +2 more
doaj   +1 more source

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Trials, 2020
Objectives We will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.
Mehdi Hassaniazad, Ali Bazram, Soheil Hassanipour, Mohammad Fathalipour   +3 more
doaj   +1 more source

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Neurology and Therapy, 2023
Introduction This study assessed the cost-effectiveness of ozanimod compared with commonly used disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS). Methods Annualized relapse rate (ARR) and safety data were obtained from
Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, Elyse Swallow, Akanksha Dua, Komal Gupte-Singh   +5 more
doaj   +1 more source

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification

Безопасность и риск фармакотерапии, 2019
Multiple sclerosis is  one  of  the  most common neurological diseases of  working age population. The last 20 years widely use drugs that change the  course of multiple sclerosis.
K. E. Zatolochina, I. I. Snegireva, A. S. Kazakov, V. K. Lepakhin   +3 more
doaj   +1 more source

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study

BMC Neurology, 2008
Background The EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study was an international, randomized, open-label, assessor-blinded, parallel-group study assessing the efficacy and tolerability of interferon (
Bennett R, AL-Sabbagh A, Traboulsee A, Chang P, Li DKB   +4 more
doaj   +1 more source

Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation

FEBS Letters, EarlyView.
Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe, Tanmay Kumar Mohanty, Rashna Bhandari, Dorothea Fiedler   +3 more
wiley   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source